Article

AJMC® Research Roundup: August 2019

Here are 5 interesting findings from the August 2019 issue of AJMC®.

Hi, I’m Christina Mattina for The American Journal of Managed Care®. Here are 5 findings from research published in the August issue.

The Potential Impact of CAR T-Cell Treatment Delays on Society

1. Treatment with CAR T-cell therapy provides significant benefit to patients with 2 types of cancers and results in billions of dollars gained in social value. But without access to treatment, patients lose large chunks of that value, leading the study authors to suggest that barriers to this therapy should be minimized.

Influence of Out-of-Network Payment Standards on Insurer—Provider Bargaining: California’s Experience

2. California’s new policy setting out-of-network payment standards for nonemergency physician services has shifted leverage in negotiations in favor of payers, who now have an incentive to cancel contracts with rates higher than the standard, according to interviews with a wide range of stakeholders.

Passive Social Health Surveillance and Inpatient Readmissions

3. Data from a social health surveillance system indicate that individuals who reported social needs (such as food insecurity or transportation needs) were more likely to have an inpatient readmission within 30, 90, and 180 days than individuals without such needs.

Access to Chiropractic Care and the Cost of Spine Conditions Among Older Adults

4. When Medicare beneficiaries moved to an area with higher accessibility of chiropractic care, there were associated decreases in spending on spine evaluation and management as well as diagnostic imaging and testing, suggesting the potential for significant savings considering the large volume of older Americans with spine conditions.

Late Diagnosis of Hepatitis C Virus Infection, 2014-2016: Continuing Missed Intervention Opportunities

5. Prompt detection and treatment of hepatitis C virus is key to achieving improved outcomes, but many infections are not diagnosed until cirrhosis or end-stage liver disease occurs, representing missed opportunities to intervene earlier in the disease process, according to a large cohort study.

To read all of these studies and more, visit AJMC.com.

Related Videos
Divya Gupta, MD
Dr Cesar Davila-Chapa
1 expert in this video
1 expert in this video
Matias Sanchez, MD
Sandra Cuellar, PharmD
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo